Baricitinib, a selective inhibitor for JAK1 and JAK2 commonly used for rheumatoid arthritis, has shown in combination with an antiviral, known as remdesivir, to decrease recovery time for patients with COVID-19, particularly those on high flow oxygen (19). The gene discussed is JAK2; the disease is COVID-19.